Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

543 ARTÍCULOS , VIENDO DEL 511 AL 525

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight

Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A.

Cells. 2022 Jun 25;11(13):2023. doi: 10.3390/cells11132023.

Inosine in Neurodegenerative Diseases: From the Bench to the Bedside

Basile MS, Bramanti P, Mazzon E.

Molecules. 2022 Jul 21;27(14):4644. doi: 10.3390/molecules27144644.

Targeting endoplasmic reticulum stress using natural products in neurological disorders

Jangra A, Verma M, Kumar D, Chandrika, Rachamalla M, Dey A, Dua K, Jha SK, Ojha S, Alexiou A, Kumar D, Jha NK.

Neurosci Biobehav Rev. 2022 Oct;141:104818. doi: 10.1016/j.neubiorev.2022.104818. Epub 2022 Aug 5.

A review of stem cell therapy: An emerging treatment for dementia in Alzheimer's and Parkinson's disease

Pradhan AU, Uwishema O, Onyeaka H, Adanur I, Dost B.

Brain Behav. 2022 Sep;12(9):e2740. doi: 10.1002/brb3.2740. Epub 2022 Aug 15.

Recent Advancements in CNS Acting Drugs: A Step Towards End of Illness

Javed MN, Pottoo FH, Naim MJ, Chawla PA.

CNS Neurol Disord Drug Targets. 2022;21(10):882-883. doi: 10.2174/187152732110220722112205.

Cell models for Alzheimer's and Parkinson's disease: At the interface of biology and drug discovery

Cetin S, Knez D, Gobec S, Kos J, Pišlar A.

Biomed Pharmacother. 2022 May;149:112924. doi: 10.1016/j.biopha.2022.112924. Epub 2022 Apr 8.

Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature

Alhowail A, Alsikhan R, Alsaud M, Aldubayan M, Rabbani SI.

Drug Des Devel Ther. 2022 Aug 31;16:2919-2931. doi: 10.2147/DDDT.S367229. eCollection 2022.

Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease

Goyal A, Verma A, Dubey N, Raghav J, Agrawal A.

J Food Biochem. 2022 Dec;46(12):e14415. doi: 10.1111/jfbc.14415. Epub 2022 Sep 15.

Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder

Nakhal MM, Aburuz S, Sadek B, Akour A.

Molecules. 2022 Oct 23;27(21):7174. doi: 10.3390/molecules27217174.

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

Kopp KO, Glotfelty EJ, Li Y, Greig NH.

Pharmacol Res. 2022 Dec;186:106550. doi: 10.1016/j.phrs.2022.106550. Epub 2022 Nov 11.

Resolvins Lipid Mediators: Potential Therapeutic Targets in Alzheimer and Parkinson Disease

Anand S, Azam Ansari M, Kumaraswamy Sukrutha S, Alomary MN, Anwar Khan A, Elderdery AY.

Neuroscience. 2022 Dec 15;507:139-148. doi: 10.1016/j.neuroscience.2022.11.001. Epub 2022 Nov 11.

Applications of nanobodies in brain diseases

Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, Raes G.

Front Immunol. 2022 Nov 8;13:978513. doi: 10.3389/fimmu.2022.978513. eCollection 2022.

Neuroprotection and Non-Invasive Brain Stimulation: Facts or Fiction?

Guidetti M, Bertini A, Pirone F, Sala G, Signorelli P, Ferrarese C, Priori A, Bocci T.

Int J Mol Sci. 2022 Nov 9;23(22):13775. doi: 10.3390/ijms232213775.

Porphyromonas gingivalis, neuroinflammation and Alzheimer's disease

Owoyele PV, Malekzadeh S.

Niger J Physiol Sci. 2022 Dec 31;37(2):157-164. doi: 10.54548/njps.v37i2.1.

Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases

Mannan A, Singh TG, Singh V, Garg N, Kaur A, Singh M.

Curr Drug Targets. 2022;23(3):286-310. doi: 10.2174/1389450122666210707120256.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias